Vir Biotechnology (VIR) Capital Expenditures (2018 - 2026)

Vir Biotechnology has reported Capital Expenditures for 9 years, with the latest figure at $390000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 76.06% year-over-year to $390000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 49.09% YoY) and the FY2025 annual result came in at $4.8 million, down 33.82% from the prior year.
• Capital Expenditures grew to $390000.0 in Q1 2026 per VIR's latest filing, from $348000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $20.6 million in Q2 2022 and troughed at $317000.0 in Q3 2025.
• A 5-year average of $6.0 million and a median of $2.5 million in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 4090.74% in 2022, then tumbled 92.96% in 2024.
• Over 5 years, Capital Expenditures stood at $12.6 million in 2022, then plunged by 87.79% to $1.5 million in 2023, then increased by 29.97% to $2.0 million in 2024, then tumbled by 82.56% to $348000.0 in 2025, then advanced by 12.07% to $390000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $390000.0, $348000.0, and $317000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.